EGFR and non-small cell lung carcinoma: However, OS was similar between the ABCP and PC arms (20.63 vs. 20.27 months, P = 0.975).421 Likewise, the updated final exploratory analysis of the IMpower-150 trial revealed no significant difference in OS between all EGFR mutation-positive NSCLC patients treated with ABCP versus BCP (chemotherapy plus bevacizumab).